Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.

Abstract

Single-dose trovafloxacin (15 mg/kg given intravenously [i.v.]) and ampicillin (40 mg/kg given i.v.) protected 38 and 33% of animals challenged with an ampicillin-tolerant strain of Streptococcus oralis, respectively. As a double-dose regimen, trovafloxacin afforded total protection (100%; P < 0.001 versus controls). Trovafloxacin is the first fluoroquinolone effective in preventing experimental streptococcal endocarditis.

• Authors: I Katsarolis, A Pefanis, D Iliopoulos, P Siaperas, P Karayiannakos, H Giamarellou
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 44 Issue 9 Pg. 2564-6 (Sep 2000) ISSN: 0066-4804 [Print] United States
• PMID: 10952619 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Naphthyridines
• Penicillins
• Ampicillin
• trovafloxacin

Topics

• Ampicillin (therapeutic use)
• Animals
• Anti-Infective Agents (therapeutic use)
• Antibiotic Prophylaxis
• Aortic Valve (microbiology)
• Disease Models, Animal
• Endocarditis, Bacterial (prevention & control)
• Female
• Fluoroquinolones
• Heart Valve Diseases (drug therapy, microbiology)
• Microbial Sensitivity Tests
• Naphthyridines (therapeutic use)
• Penicillins (therapeutic use)
• Rabbits
• Streptococcal Infections (prevention & control)
• Streptococcus (drug effects)